BrickBio, Inc.
Zhi Li is a seasoned professional with over 20 years of experience in the biotechnology and pharmaceutical industries. Currently serving as Director and Senior Scientist at BrickBio, Inc. since January 2020, Zhi Li specializes in cell line development. Prior to this role, Zhi Li worked at Takeda from July 2000 to January 2020 as Scientist II, focusing on small molecule drug and therapeutic antibody discovery and development.
This person is not in any teams
BrickBio, Inc.
BrickBio is a developer of a bioconjugation platform intended for research of site-specific modification of proteins. The company's platform can optimize any conjugate with the selective modification of a number of distinct websites on a single protein through its prokaryotic and eukaryotic expression programs, thereby providing hospitalswith amino acid coupled therapeutics to improve protein characteristics.